Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 78 full-time employees. The firm is focused on developing cell therapies to address unmet medical needs. The company designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. The company has five allogeneic product candidates: OpRegen, OPC1, VAC2, ANP1, and PNC1. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy in a Phase IIa development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). OPC1 is an oligodendrocyte progenitor cell therapy in a Phase I/IIa development for the treatment of acute spinal cord injuries (SCI); VAC is a dendritic cell therapy produced from Lineages VAC technology platform for immuno-oncology and infectious disease, in Phase I clinical development for the treatment of non-small cell lung cancer.